2023 Partners
resistanceBio
Expertise Partner
resistanceBio is a target and drug discovery platform company focused on identifying novel therapies that overcome treatment-resistant cancer and enable personalized precision medicine.
Platform: We’ve developed an in vitro and ex vivo cancer evolution model (the ResCu system®) that maps the cancer resistome by mimicking natural tumor response to treatment. ResCu and patient data combine to create our cancer resistome database. ResCu allows us to exploit novel cancer and immuno-oncology targets through deep learning and biological validation for better therapeutic outcomes for patients.
Biodesix®
Expertise Partner
Biodesix® is an experienced partner in the field of blood-based molecular diagnostic testing. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by interpreting genomic and proteomic information from both tumor biology and the patient’s immune response. Biodesix enables our partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategies.
Promega
Program Partner
We share your passion for science. Promega is a world leader in providing innovative solutions in the life sciences. We develop bioluminescent technologies that deliver more biologically-relevant data for small and large molecule drug discovery. Learn how our biochemical and cell-based assays are used to target the RAS signaling pathway, kinases, protein degradation, inflammasome, and many other hot targets.
Tempus
Program Partner
Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios.
LIDE Biotech
Exhibition Partner
LIDE Biotech is a Shanghai-based, AAALAC award winning oncology contract research provider with 12 years of delivering drug evaluation services to 200+ clients worldwide. We offer preclinical CRO services like pharmacology, PK and biomarker studies with 70+ CDX models and 1900 PDX models. Our library covers 50+ cancer types and 200+ pretreated models that harbor special naturally-occurred drug resistance and/or genetic alterations. We also have proprietary tools offering in-vivo drug validation in 7-10 days.
Nanome
Exhibition Partner
Nanome is changing how we understand, design, and interact with science. Nanome’s immersive virtual workspaces allow users to visualize, modify, and simulate chemical compounds, proteins, and nucleic acids to help improve the Drug Discovery process. Our virtual reality platform facilitates communication of structural data in drug discovery which has proved beneficial to pharmaceutical and biotech companies across the globe. This is especially helpful for organizations that are interested in improving their cross-site collaboration.
Certis Oncology
Exhibition Partner
Certis Oncology Solutions is the only translational partner that combines the predictive power of artificial intelligence with advanced preclinical cancer models to evaluate efficacy and understand the complex mechanisms of action inherent to drugs that target RAS pathways. Stop by our exhibit booth and afternoon poster session on Day One to talk to us about your novel drug development strategies and how we can help validate and accelerate your RAS-targeted compounds.
Genialis
Event Partner
Genialis is a data science company putting people first to develop more effective drugs, and to allow us to make more targeted treatment decisions for better outcomes.
Genialis ResponderID™ is a biomarker discovery platform that employs a people-first framework to model underlying disease biology. The platform marries this novel approach to biomarker conceptualization with proprietary technology, validated signatures and human data. The result is biomarkers that work in real patient populations and scale across clinical settings.
